Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Trevi Therapeutics, Inc. (TRVI)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, general and administrative [+] | 8.4 | 7.6 | 2.3 | 2.6 | 7.8 | 7.0 | 2.1 | 2.2 |
| General and administrative | | | 2.3 | 2.6 | | | 2.1 | 2.2 |
| Research and development | | | 4.3 | 5.8 | | | 6.2 | 4.7 |
| Other operating expenses | -2.4 | -1.0 | | | 0.5 | 0.6 | | |
| EBITDA [+] | -5.9 | -6.6 | -6.7 | -8.4 | -8.3 | -7.6 | -8.3 | -6.9 |
| EBITDA growth | -28.4% | -14.1% | -19.6% | 21.1% | -9.5% | -5.5% | -9.5% | -4.1% |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -6.0 | -6.6 | -6.7 | -8.4 | -8.3 | -7.6 | -8.3 | -6.9 |
| EBIT growth | -28.0% | -14.0% | -19.5% | 21.0% | -9.5% | -5.5% | -10.0% | -4.1% |
| Interest expense | | | 0.3 | 0.3 | | | 0.3 | 0.3 |
| Interest expense | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Other income (expense), net [+] | -1.1 | 0.4 | 1.4 | 0.4 | 0.5 | 0.6 | 0.1 | 0.0 |
| Other non-ooperating expenses | | | | | | | 0.4 | |
| Other | | 0.2 | | | | | | |
| Pre-tax income | -7.2 | -6.4 | -5.5 | -8.3 | -8.1 | -7.3 | -8.5 | -7.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.4% | 0.1% | 0.4% | 0.1% | 0.0% | 0.1% | 0.1% | |
| Net income | -7.1 | -6.4 | -5.5 | -8.3 | -8.1 | -7.3 | -8.5 | -7.3 |
| |
| Basic EPS [+] | ($0.07) | ($0.06) | ($0.09) | ($0.12) | ($0.14) | ($0.24) | ($0.37) | ($0.34) |
| Growth | -46.5% | -72.7% | -77.1% | -64.3% | -72.2% | -44.8% | -29.3% | -17.5% |
| Diluted EPS [+] | ($0.07) | ($0.06) | ($0.09) | ($0.12) | ($0.14) | ($0.24) | ($0.37) | ($0.34) |
| Growth | -46.5% | -72.7% | -77.1% | -64.3% | -72.2% | -44.8% | -29.3% | -17.5% |
| |
| Shares outstanding (basic) [+] | 98.7 | 98.6 | 64.5 | 68.9 | 59.5 | 30.8 | 22.8 | 21.6 |
| Growth | 65.8% | 220.1% | 182.6% | 218.9% | 195.9% | 58.7% | 26.5% | 19.2% |
| Shares outstanding (diluted) [+] | 98.7 | 98.6 | 64.5 | 68.9 | 59.5 | 30.8 | 22.8 | 21.6 |
| Growth | 65.8% | 220.1% | 182.6% | 218.9% | 195.9% | 58.7% | 26.5% | 19.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|